Cargando…

Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction

Because sildenafil citrate is a treatment, not a cure, for erectile dysfunction (ED), many men may choose to use it for an extended period. Men with ED who had previously completed 1 of 4 double-blind trials with short-term open-label extension (combined duration, 0.9–1.2 years) were eligible for th...

Descripción completa

Detalles Bibliográficos
Autores principales: McMurray, James G, Feldman, Robert A, Auerbach, Stephen M, DeRiesthal, Herb, Wilson, Neal
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2387281/
https://www.ncbi.nlm.nih.gov/pubmed/18516312
_version_ 1782155304849375232
author McMurray, James G
Feldman, Robert A
Auerbach, Stephen M
DeRiesthal, Herb
Wilson, Neal
author_facet McMurray, James G
Feldman, Robert A
Auerbach, Stephen M
DeRiesthal, Herb
Wilson, Neal
author_sort McMurray, James G
collection PubMed
description Because sildenafil citrate is a treatment, not a cure, for erectile dysfunction (ED), many men may choose to use it for an extended period. Men with ED who had previously completed 1 of 4 double-blind trials with short-term open-label extension (combined duration, 0.9–1.2 years) were eligible for this 4-year, open-label, extension study, which assessed the safety and effectiveness of flexible doses (25, 50, and 100 mg sildenafil) used as needed. Adverse events that were serious or led to dosing changes or discontinuation (temporary or permanent) were recorded. Many of the 979 participants (mean age, 58 [range, 27–82] years; mean ED duration, 4.5 years) had concomitant hypertension (28%), diabetes (22%), or hyperlipidemia (14%). Overall, 37 (3.8%) had treatment-related adverse events (none serious) requiring dosage change or discontinuation and 62 (6.3%) discontinued because of insufficient response. At each yearly assessment, more than 94% of participants responded affirmatively to the questions: “Are you satisfied with the effect of treatment on your erections?” and “If yes, has treatment improved your ability to engage in sexual activity?” These results argue against the loss of tolerability or the development of tachyphylaxis over a prolonged period of as needed, flexible-dose sildenafil treatment of men with ED.
format Text
id pubmed-2387281
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-23872812008-05-30 Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction McMurray, James G Feldman, Robert A Auerbach, Stephen M DeRiesthal, Herb Wilson, Neal Ther Clin Risk Manag Original Research Because sildenafil citrate is a treatment, not a cure, for erectile dysfunction (ED), many men may choose to use it for an extended period. Men with ED who had previously completed 1 of 4 double-blind trials with short-term open-label extension (combined duration, 0.9–1.2 years) were eligible for this 4-year, open-label, extension study, which assessed the safety and effectiveness of flexible doses (25, 50, and 100 mg sildenafil) used as needed. Adverse events that were serious or led to dosing changes or discontinuation (temporary or permanent) were recorded. Many of the 979 participants (mean age, 58 [range, 27–82] years; mean ED duration, 4.5 years) had concomitant hypertension (28%), diabetes (22%), or hyperlipidemia (14%). Overall, 37 (3.8%) had treatment-related adverse events (none serious) requiring dosage change or discontinuation and 62 (6.3%) discontinued because of insufficient response. At each yearly assessment, more than 94% of participants responded affirmatively to the questions: “Are you satisfied with the effect of treatment on your erections?” and “If yes, has treatment improved your ability to engage in sexual activity?” These results argue against the loss of tolerability or the development of tachyphylaxis over a prolonged period of as needed, flexible-dose sildenafil treatment of men with ED. Dove Medical Press 2007-12 2007-12 /pmc/articles/PMC2387281/ /pubmed/18516312 Text en © 2007 Dove Medical Press Limited. All rights reserved
spellingShingle Original Research
McMurray, James G
Feldman, Robert A
Auerbach, Stephen M
DeRiesthal, Herb
Wilson, Neal
Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction
title Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction
title_full Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction
title_fullStr Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction
title_full_unstemmed Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction
title_short Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction
title_sort long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2387281/
https://www.ncbi.nlm.nih.gov/pubmed/18516312
work_keys_str_mv AT mcmurrayjamesg longtermsafetyandeffectivenessofsildenafilcitrateinmenwitherectiledysfunction
AT feldmanroberta longtermsafetyandeffectivenessofsildenafilcitrateinmenwitherectiledysfunction
AT auerbachstephenm longtermsafetyandeffectivenessofsildenafilcitrateinmenwitherectiledysfunction
AT deriesthalherb longtermsafetyandeffectivenessofsildenafilcitrateinmenwitherectiledysfunction
AT wilsonneal longtermsafetyandeffectivenessofsildenafilcitrateinmenwitherectiledysfunction
AT longtermsafetyandeffectivenessofsildenafilcitrateinmenwitherectiledysfunction